skip to Main Content

STERN LABORATORY

Research

Stern AM, Yang Y, Meunier AL, Liu W, Cai Y, Ericsson M, Goedert M, Scheres SHW, Selkoe DJ. Abundant Aβ Fibrils in Ultracentrifugal Supernatants of Aqueous Extracts From Alzheimer’s Disease Brain. Neuron 2023 Jul 5;111(13):2012-2020.e4.

Stern AM,* Van Pelt K,* Liu L, Anderson AK, Ostaszewski B, Mapstone M, O’Bryant S, Petersen ME, Christian BT, Handen BL, Selkoe DJ, Schmitt F, Head E, and the Alzheimer’s Biomarker Consortium –  Down Syndrome (ABC-DS). Plasma NT1-Tau and Aβ42 Correlate With Age and Cognitive Function in Two Large Down Syndrome Cohorts. Alzheimer’s Dement 2023 Mar 10. (in press)

Stern AM, Liu L, Jin S, Liu W, Meunier AL, Ericsson M, Miller MB, Batson M, Sun T, Kathuria S, Reczek D, Pradier L, Selkoe DJ. Calcium-Sensitive Antibody Isolates Soluble Amyloid-Β Aggregates and Fibrils From Alzheimer’s Disease Brain. Brain 2022 Jul 29;145(7):2528-2540.

Liu L, Kwak H, Lawton TL, Jin SX, Meunier AL, Dang Y, Ostaszewski B, Pietras AC, Stern AM, and Selkoe DJ. An Ultra-Sensitive Immunoassay Quantifies Soluble Aβ Oligomers in Human Brain, CSF, and Plasma. Alzheimer’s Dement. 2022 Jun;18(6):1186-1202.

Commentaries and Reviews

Stern AM and Sperling RA. “Tangles, Not TANGO: Targeting Tau Aggregates.” Nat Aging. 2021 Nov 27. (in press)

Stern AM and Selkoe DJ. Soluble Oligomers or Insoluble Fibrils? Scientific Commentary on “Tau Seeding and Spreading in vivo is Supported by both AD-Derived Fibrillar and Oligomeric Tau.” Acta Neuropathol. 2023 Sep 21. (in press)

Stern AM. Anti-Dementia Bias and Medicare Regulation of Alzheimer’s Disease Care. Alzheimers Dement. 2023 Aug;19(8):3752-3753.

Stern AM and Selkoe DJ. Unfairness to Patients With Alzheimer Disease in Medicare’s Coverage of Antiamyloid Immunotherapy. JAMA Neurol. 2022 Oct 1;79(10):962-963.

Li S and Stern AM. (2022) Bioactive Human Alzheimer Brain Soluble Aβ: Pathophysiology and Therapeutic Opportunities. Mol Psychiatry. 2022 Aug;27(8):3182-3191.

Back To Top